USANA Health Sciences, Inc. announced financial results for its fiscal third quarter ended October 1, 2022. Key Financial & Operating Results:
Third quarter net sales were $233 million as compared with $274 million during the third quarter of the prior year. Third quarter diluted EPS totaled $0.78 versus $1.36 during the third quarter of 2021. Company revises fiscal 2022 net sales and diluted EPS outlook to $955 million to $975 million and $3.15 to $3.40, respectively.
Q3 2022 Financial Performance – Consolidated Results
Net Sales $233 million
-15% vs. prior-year quarter
-9% constant currency vs. prior-year quarter
-$15 million YOY FX impact, or -6%
-9% sequentially in constant currency
Diluted EPS $0.78 -43% vs. prior-year quarter -22% sequentially
Diluted shares of 19.3 million, -4% year-over-year
Active Customers 474,000 -18% vs. prior-year quarter -15% sequentially
“The challenging operating environment in Asia Pacific and the strengthening U.S. dollar negatively affected our operating results in the third quarter,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“COVID-related disruptions and challenging economic conditions resulting from those disruptions negatively impacted our results in several key Asia Pacific markets where city-wide lockdowns and other COVID restrictions persisted. This difficult operating environment has impacted our entire industry.”
Guest continued,
“While we remain committed to our long-term business strategy,